Allergy Therapeutics (AGY)

 

Latest News

Holdings in Company

RNS Number: 5221B Allergy Therapeutics PLC 10 January 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Allergy The...

Allergy Therapeutics completes recruitment for clinical study

Allergy Therapeutics said recruitment of the group's phase III clinical trial with PQ Birch (PQBirch301) has been completed...

PQ Birch Phase III trial completes recruitment

RNS Number: 2889B Allergy Therapeutics PLC 09 January 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") PQ Birch Phase III clinical trial completes recruitment 9 January 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces that recruitment of the Gro...

Allergy Therapeutics co-development agreement with Ergomed

Allergy Therapeutics has entered into a co-development collaboration agreement with Ergomed for the clinical developme...

All News

DateHeadlineSource
30-12-16Grant of AwardsRNS
25-11-16Allergy Therapeutics resolutions passed at AGMStockMarketWire
24-11-16Result of AGMRNS
02-11-16Allergy Therapeutics granted EU patent StockMarketWire
02-11-16EU Patent Office grants patent for MCTRNS
27-10-16Issue of equity in respect of exercise of optionsRNS
24-10-16Annual Report and AccountsRNS
14-10-16Share of the week: Tipped to double againInteractive Investor
10-10-16New data from novel adjuvant systemRNS
03-10-16Issue of equity in respect of exercise of optionsRNS
29-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
29-09-16Director/PDMR ShareholdingRNS
28-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
28-09-16Director/PDMR ShareholdingRNS
26-09-16Allergy Therapeutics tipped to bounce backInteractive Investor
26-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
26-09-16Director/PDMR ShareholdingRNS
26-09-16Hardman Research: Performance drives market shareRNS
26-09-16Allergy Therapeutics revenues up StockMarketWire
26-09-16Allergy Therapeutics revenues up StockMarketWire
26-09-16Allergy Therapeutics Preliminary ResultsRNS
21-09-16Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLCStockMarketWire
21-09-16Allergy Therapeutics options exercised StockMarketWire
20-09-16Issue of equity in respect of exercise of optionsRNS
05-09-16Allergy Therapeutics schedules FY results StockMarketWire
05-09-16Notice of Preliminary ResultsRNS
31-08-16Allergy Therapeutics Plc to present at the Shares Investor Evening in London on 27th September 2016StockMarketWire
13-07-16Trading UpdateRNS
08-07-16Results of mite immunotherapy Acarovac PlusTRNS
27-06-16Findings from mEEC dose range finding study G204RNS
13-06-16Allergy Therapeutics' satellite symposium at EAACIStockMarketWire
13-06-16Allergy hosts Satellite Symposium at EAACIRNS
10-06-16Appointment of Finance DirectorRNS
18-05-16Why GlaxoSmithKline plc, Allergy Therapeutics plc and Consort Medical plc are a dying breedMotley Fool
09-05-16Allergy Therapeutics positive data from PQBirch204 studyStockMarketWire
09-05-16Positive Phase II DataRNS
21-04-16This list of shares keeps outperformingInteractive Investor
23-03-16Allergy Therapeutics options exercised StockMarketWire
23-03-16Issue of equity in respect of options exerciseRNS
17-03-16Allergy Therapeutics FD resigns StockMarketWire

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account